Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.67 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | ACACA | Q13085 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6752282 | 0.91 | KDM4E (0.73) | KDM4EDYRK1AMEN1KMT2AL3MBTL1 | |
| SCHEMBL10051515 | 0.84 | MEN1 (0.60) | KDM4EMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL9013572 | 0.84 | KDM4E (0.53) | KDM4EDYRK1AMEN1KMT2AAURKA | |
| SCHEMBL1644753 | 0.83 | DYRK1A (0.71) | KDM4EDYRK1ANPC1RAB9AALDH1A1 | |
| SCHEMBL26967691 | 0.82 | KDM4E (0.54) | KDM4EDYRK1AMEN1KMT2AAURKA | |
| SCHEMBL1644543 | 0.81 | MEN1 (0.50) | KDM4EDYRK1AMEN1KMT2AL3MBTL1 | |
| SCHEMBL3451188 | 0.81 | KDM4E (0.49) | KDM4EMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL3450627 | 0.79 | KDM4E (0.70) | KDM4EMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL2175274 | 0.79 | MEN1 (0.72) | KDM4EMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL30230259 | 0.79 | KDM4E (0.69) | KDM4EMEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1796673-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | claimed |
| WO-2006034473-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20240199654-A1 | CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF | SUZHOU GUOKUANG PHARMTECH. CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| EP-4310081-A1 | CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF | Suzhou Guokuang Pharmtech. Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| EP-4310081-A1 | CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF | Suzhou Guokuang Pharmtech. Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| CN-117157284-A | CTLA-4 small molecule degradation agent and application thereof | 苏州国匡医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-3362451-B1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-04-12 | — | — | EP | disclosed |
| WO-2022194248-A1 | CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF | 苏州国匡医药科技有限公司 | 2022-09-22 | — | — | WO | disclosed |
| CN-110446711-B | Inhibitors of influenza virus replication and uses thereof | 广东东阳光药业有限公司 | 2022-02-15 | — | — | CN | disclosed |
| US-11225477-B2 | Inhibitors of influenza virus replication, application methods and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-01-18 | — | — | US | disclosed |
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | disclosed |
| WO-2006034473-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-6706215-B1 | 2-(2'-HYDROXYPHENYL)-1,3-PYRIMIDINE DERIVATIVE | CIBA SPECIALTY CHEMICALS CORPORATION | 2004-03-16 | — | — | US | disclosed |
| US-6372751-B1 | DRUGS WITH BENZENE AND PYRIMIDINE RINGS | BERLEX LABORATORIES, INC. | 2002-04-16 | — | — | US | disclosed |
| EP-1135131-A4 | ARYL AND HETEROCYCLYL SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LAB (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1135131-A1 | ARYL AND HETEROCYCLYL SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6127376-A | A BLOOD FACTOR XA ENZYME INHIBITOR TREATING A HUMAN HAVING A DISEASE-STATE CHARACTERIZED BY THROMBOTIC ACTIVITY | BERLEX LABORATORIES, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| WO-2000033844-A1 | ARYL AND HETEROCYCLYL SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LATORATORIES, INC. (US) | 2000-06-15 | — | — | WO | disclosed |
| US-5753729-A | COATING COMPOSITION COMPRISING ORGANIC POLYMER BINDER, 2-(2*-HYDROXYPHENYL)PYRIMIDINE STABILIZER | CIBA SPECIALTY CHEMICALS CORPORATION | 1998-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | UMPS, DPYD, TYMS | KDM4E 3484/4885DYRK1A 3933/4885MEN1 4470/4885 |
| US-11225477-B2 | Inhibitors of influenza virus replication, application methods and uses thereof | POLRMT, EIF2AK2, POLM | KDM4E 1334/4885DYRK1A 2813/4885MEN1 4473/4885 |
| US-20240199654-A1 | CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF | CD274, PDCD1, PDCD1LG2 | KDM4E 174/4885DYRK1A 1038/4885MEN1 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.